Allo-QuadCAR01-T

· AvenCell Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Allo-QuadCAR01-T, covering 2026-04-02 to 2026-04-02. Get the full timeline:

Most recent: Clinical Trial Update: Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]

See pricing